Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

RxSight Affirms FY2025 Sales Guidance of $120.00M-$130.00M vs $167.58M Est

Author: Benzinga Newsdesk | August 07, 2025 03:06pm
RxSight (NASDAQ:RXST) affirms FY2025 sales outlook from $120.00 million-$130.00 million to $120.00 million-$130.00 million vs $167.58 million estimate.

Posted In: RXST


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist